|
| Author | Vein insufficiency | Intervention | Control | Postprocedural management | DUS scan finding | Follow-up period (percentage lost-to follow-up in groups MOCA and thermal ablation) | Adverse event identification |
|
| Holewijn et al. 2017 [13] | GSV | MOCA using ClariVein and polidocanol 3% 2 ml for the first 10-15 cm and 1.5% for the remainder. Pullback rate 7 s/cm | RFA using Closurefast | Phlebotomy as indicated, stocking compression for 2 weeks | Complete occlusion, partial recanalization >10 cm, complete recanalization | 1 month (0% & 0%), 12 months (21.4% & 30.1%), 24 months (26.2% & 21.4%) | Major: DVT, pulmonary embolism, skin burn, saphenous neuralgia
Minor: phlebitis, induration, hematoma, hyperpigmentation |
|
| Vähäaho et al. 2019 [14] | GSV | MOCA using ClariVein and STS 1.5%. Pullback rate was not defined | RFA using Closurefast or EVLA using ELVes 1470-nm diode radial laser | Phlebotomy for every patient. Other postprocedural management was not defined | Complete occlusion, proximal occlusion, distal occlusion, complete recanalization | 1 month (0% & 0%), 12 months (18.2% & 6.1%) | Major: DVT, nerve injury
Minor: hyperpigmentation, hematoma, phlebitis, lumps |
|
| Bootun et al. 2016 [15] | GSV, SSV | MOCA using ClariVein and STS 2%. Pullback rate was not defined | RFA using Venefit | Phlebotomy as indicated, stocking compression for 2 weeks | Complete occlusion, proximal occlusion, distal occlusion, complete recanalization | 1 month (13.3% & 55.9%) | Major: DVT
Minor: phlebitis |
|
| Lane et al. 2016 [16] | GSV, SSV | MOCA using ClariVein and STS 2%. Pullback rate 7 s/cm | RFA using Venefit | Phlebotomy as indicated, LMWH administration, stocking compression for 2 weeks | Complete occlusion, proximal occlusion, distal occlusion, complete recanalization | 1 month (16.9% & 26.8%), 6-months (25.3% & 28%) | Major: DVT, sensory disturbance
Minor: phlebitis, hyperpigmentation |
|
